<?xml version="1.0" standalone="no"?>
<!DOCTYPE ALGORITHM SYSTEM 
	"http://hivdb6.stanford.edu/asi/xml/ASI.dtd">

<ALGORITHM>

	<ALGNAME>IASUSA</ALGNAME>

	<ALGVERSION>201012</ALGVERSION>

	<DEFINITIONS>

		<GENE_DEFINITION>
		   <NAME>PR</NAME>
		   <DRUGCLASSLIST>PI</DRUGCLASSLIST>
		</GENE_DEFINITION>
		<GENE_DEFINITION>
		   <NAME>RT</NAME>
		   <DRUGCLASSLIST>NNRTI,NRTI</DRUGCLASSLIST>
		</GENE_DEFINITION>
		<GENE_DEFINITION>
		   <NAME>IN</NAME>
		   <DRUGCLASSLIST>IH</DRUGCLASSLIST>
		</GENE_DEFINITION>
		<GENE_DEFINITION>
		   <NAME>GP41</NAME>
		   <DRUGCLASSLIST>EI</DRUGCLASSLIST>
		</GENE_DEFINITION>
  
  		<!-- only one level used, since results are purely descriptive.  Level code and text are constants in results -->
		<LEVEL_DEFINITION>
			<ORDER>1</ORDER>
			<ORIGINAL>Mutation list comprises ones in the IAS chart, for this drug, that are found in this sequence</ORIGINAL>
			<SIR>I</SIR>
		</LEVEL_DEFINITION>

		<DRUGCLASS>
			<NAME>PI</NAME>
			<DRUGLIST>ATV,ATV/r,DRV/r,FPV/r,IDV/r,LPV/r,NFV,SQV/r,TPV/r</DRUGLIST>
		</DRUGCLASS>
		<DRUGCLASS>
			<NAME>NRTI</NAME>
			<DRUGLIST>RT69i_multi,RT151_multi,TAM_multi,ABV,DDI,FTC,3TC,D4T,TDF,ZDV</DRUGLIST>
				<!-- FTC=Emtricitabine; 3TC=Lamivudine; D4T=Stavudine; AZT=ZDV  -->
		</DRUGCLASS>
		<DRUGCLASS>
			<NAME>NNRTI</NAME>
			<DRUGLIST>NVP,EFV,ETR</DRUGLIST>
		</DRUGCLASS>
		<DRUGCLASS>
			<NAME>IH</NAME>
			<DRUGLIST>RAL</DRUGLIST>	
		</DRUGCLASS>
		<DRUGCLASS>
			<NAME>EI</NAME>
			<DRUGLIST>ENF</DRUGLIST>
		</DRUGCLASS>
 
 		<!-- there is only one level, so all point values map to it -->
		<GLOBALRANGE>
			 ( -INF TO INF => 1 )
		</GLOBALRANGE>

	<!-- the comments are the text of footnotes in the IASUSA document; 
		 they will appear for sequences having the relevant mutations.
		 Footnotes not referring to specific mutations are not included. -->
			 
		<COMMENT_DEFINITIONS>
			
		 	<COMMENT_STRING id="UserNote_a">
				<TEXT>User Note a: Some nucleoside (or nucleotide) analogue reverse transcriptase inhibitor (nRTI) mutations, like T215Y and H208Y,[1] may lead to viral hypersusceptibility to the nonnucleoside analogue reverse transcriptase inhibitors (NNRTIs), including etravirine,[2] in nRTI-treated individuals. The presence of these mutations may improve subsequent virologic response to NNRTI-containing regimens (nevirapine or efavirenz) in NNRTI-naive individuals,[3-7] although no clinical data exist for improved response to etravirine in NNRTI-experienced individuals.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_b">
				<TEXT>User Note b: The 69 insertion complex consists of a substitution at codon 69 (typically T69S) and an insertion of 2 or more amino acids (SS, SA, SG or others). The 69 insertion complex is associated with resistance to all nRTIs currently approved by the US FDA when present with one or more thymidine analogue associated mutations (TAMs) at codons 41, 210, or 215.[8] Some other amino acid changes from the wildtype T at codon 69 without the insertion may be associated with broad nRTI resistance.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_c">
				<TEXT>User Note c: Tenofovir retains activity against the Q151M complex of mutations.[8]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_d">
				<TEXT>User Note d: Mutations known to be selected by thymidine analogues (M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E, termed TAMs) also confer reduced susceptibility to all approved nRTIs.[9] The degree to which cross-resistance is observed depends on the specific mutations and number of mutations involved.[10-13]Mutations at the C-terminal reverse transcriptase domains (amino acids 293-560) outside of regions depicted on the figure bars may prove to be important for HIV-1 drug resistance. However, to date clinical relevance of these in vitro findings has not been established [14] because the connection domain mutations arise mostly in conjunction with TAMs and M184V and do not seem to have major independent effects.[15]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
	
			<COMMENT_STRING id="UserNote_e">
				<TEXT>User Note e: Although reverse transcriptase changes associated with the E44D and V118I mutations may have an accessory role in increased resistance to nRTIs in the presence of TAMs, their clinical relevance is very limited.[16-18]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_f">
				<TEXT>User Note f: The M184V mutation alone does not appear to be associated with a reduced virologic response to abacavir in vivo.[19,20] When associated with TAMs, M184V increases abacavir resistance.[19,20]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_g">
				<TEXT>User Note g: As with tenofovir, the K65R mutation may be selected by didanosine, abacavir, or stavudine (particularly in patients with nonsubtype-B clades) and is associated with decreased viral susceptibility to these drugs.[19,21,22] Data are lacking on the potential negative impact of K65R on clinical response to didanosine.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_h">
				<TEXT>User Note h: The presence of 3 of the following mutations (M41L, D67N, L210W, T215Y/F, K219Q/E) is associated with resistance to didanosine.[23] The presence of K70R or M184V alone does not decrease virologic response to didanosine.[24]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_i">
				<TEXT>User Note i: K65R is selected frequently (4%-11%) in patients with nonsubtype-B clades for whom stavudine-containing regimens are failing in the absence of tenofovir.[25,26]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_j">
				<TEXT>User Note j: The presence of M184V appears to delay or prevent emergence of TAMs.[27] This effect may be overcome by an accumulation of TAMs or other mutations.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_k">
				<TEXT>User Note k: The T215A/C/D/E/G/H/I/L/N/S/V substitutions are revertant mutations at codon 215 that confer increased risk of virologic failure of zidovudine or stavudine in antiretroviral-naive patients.[28-30] The T215Y mutant may emerge quickly from 1 of these mutations in the presence of zidovudine or stavudine.[31,32]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_l">
				<TEXT>User Note l: The presence of K65R is associated with a reduced virologic response to tenofovir.[8] A reduced response also occurs in the presence of 3 or more TAMs inclusive of either M41L or L210W.[8] The presence of TAMs or combined treatment with zidovudine prevents the emergence of K65R in the presence of tenofovir.[33-35]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_m">
				<TEXT>User Note m: The sequential use of nevirapine and efavirenz (in either order) is not recommended because of cross-resistance between these drugs.[36]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_n">
				<TEXT>User Note n: Resistance to etravirine has been extensively studied only in the context of coadministration with darunavir/ritonavir. In this context, mutations associated with virologic outcome have been assessed and their relative weights (or magnitudes of impact) assigned. In addition, phenotypic cutoff values have been calculated, and assessment of genotype-phenotype correlations from a large clinical database have determined relative importance of the various mutations. These 2 approaches are in agreement for many, but not all, mutations and weights.[37-39] The single mutations Y181C*/I*/V*, K101P*, and L100I* reduce but do not preclude clinical utility. Asterisks are used to emphasize their higher relative weights with regard to reduced susceptibility and reduced clinical response when compared with the other etravirine mutations. [40] The presence of K103N alone does not affect etravirine response.[41] Accumulation of several mutations results in greater reductions in susceptibility and virologic response than do single mutations.[42,43]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_o">
				<TEXT>User Note o: Often, numerous mutations are necessary to substantially impact virologic response to a ritonavir-boosted protease inhibitor (PI).[44] In some specific circumstances, atazanavir might be used unboosted. In such cases, the mutations that are selected are the same as with ritonavir-boosted atazanavir, but the relative frequency of mutations may differ.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_p">
				<TEXT>User Note p: Resistance mutations in the protease gene are classified as major or minor. Major mutations in the protease gene are defined as those selected first in the presence of the drug or those substantially reducing drug susceptibility. These mutations tend to be the primary contact residues for drug binding. Minor mutations generally emerge later than major mutations and by themselves do not have a substantial effect on phenotype. They may improve replication of viruses containing major mutations. Some minor mutations are present as common polymorphic changes in HIV-1 nonsubtype-B clades.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_q">
				<TEXT>User Note q: Ritonavir is not listed separately, as it is currently used only at low dose as a pharmacologic booster of other PIs.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_r">
				<TEXT>User Note r: Many mutations are associated with atazanavir resistance. Their impacts differ, with I50L, I84V, and N88S having the greatest effect. Higher atazanavir levels obtained with ritonavir boosting increase the number of mutations required for loss of activity. The presence of M46I plus L76V might increase susceptibility to atazanavir when no other related mutations are present.[45]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_s">
				<TEXT>User Note s: HIV-1 RNA response to ritonavir-boosted darunavir correlates with baseline susceptibility and the presence of several specific PI mutations. Reductions in response are associated with increasing numbers of the mutations indicated in the figure bar. The negative impact of the protease mutations I47V, I54M, T74P, and I84V and the positive impact of the protease mutation V82A on virologic response to darunavir/ritonavir were shown in 2 data sets independently. [46,47] Some of these mutations appear to have a greater effect on susceptibility than others (eg, I50V vs V11I). A median darunavir phenotypic fold change greater than 10 (low clinical cutoff) occurs with 3 or more of the 2007 IAS USA mutations listed for darunavir [48] and is associated with a diminished virologic response.[49]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_t">
				<TEXT>User Note t: The mutations depicted on the figure bar cannot be considered comprehensive because little relevant research has been reported in recent years to update the resistance and cross-resistance patterns for this drug.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_u">
				<TEXT>User Note u: In PI-experienced patients, the accumulation of 6 or more of the mutations indicated on the figure bar is associated with a reduced virologic response to lopinavir/ritonavir.[50,51] The product information states that accumulation of 7 or 8 mutations confers resistance to the drug.[52] However, there is emerging evidence that specific mutations, most notably I47A (and possibly I47V) and V32I, are associated with high level resistance.[53-55] The addition of L76V to 3 PI resistance associated mutations substantially increases resistance to lopinavir/ritonavir.[45]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_v">
				<TEXT>User Note v: In some nonsubtype-B HIV-1, D30N is selected less frequently than are other PI mutations.[56]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_w">
				<TEXT>User Note w: Clinical correlates of resistance to tipranavir are limited by the paucity of clinical trials and observational studies of the drug. The available genotypic scores have not been validated on large, diverse patient populations. The presence of mutations L24I, I50L/V, F53Y/L/W, I54L, and L76V have been associated with improved virologic response to tipranavir in some studies.[57-59]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_x">
				<TEXT>User Note x: Resistance to enfuvirtide is associated primarily with mutations in the first heptad repeat (HR1) region of the gp41 envelope gene. However, mutations or polymorphisms in other regions of the envelope (eg, the HR2 region or those yet to be identified) as well as coreceptor usage and density may affect susceptibility to enfuvirtide.[60-62]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_y">
				<TEXT>User Note y: The activity of CC chemokine receptor 5 (CCR5) antagonists is limited to patients with virus that uses only CCR5 for entry (R5 virus). Viruses that use both CCR5 and CXC chemokine receptor 4 (CXCR4; termed dual/mixed [D/M]) or only CXCR4 (X4 virus) do not respond to treatment with CCR5 antagonists. Virologic failure of these drugs frequently is associated with outgrowth of D/M or X4 virus from a preexisting minority population present at levels below the limit of assay detection. Mutations in HIV-1 gp120 that allow the virus to bind to the drug-bound form of CCR5 have been described in viruses from some patients whose virus remained R5 after virologic failure of a CCR5 antagonist. Most of these mutations are found in the V3 loop, the major determinant of viral tropism. There is as yet no consensus on specific signature mutations for CCR5 antagonist resistance, so they are not depicted in the figure. Some CCR5 antagonist-resistant viruses selected in vitro have shown mutations in gp41 without
				mutations in V3; the clinical significance of such mutations is not yet known.</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
			<COMMENT_STRING id="UserNote_z">
				<TEXT>User Note z: Raltegravir failure is associated with integrase mutations in at least 3 distinct genetic pathways defined by 2 or more mutations including (1) a signature (major) mutation at Q148H/K/R, N155H, or Y143R/H/C; and (2) 1 or more additional minor mutations. Minor mutations described in the Q148H/K/R pathway include L74M plus E138A, E138K, or G140S. The most common mutational pattern in this pathway is Q148H plus G140S, which also confers the greatest loss of drug susceptibility. Mutations described in the N155H pathway include this major mutation plus either L74M, E92Q, T97A, E92Q plus T97A, Y143H, G163K/R, V151I, or D232N.[63]  The Y143R/H/C mutation is uncommon.[64-68]  Another major mutation, E92Q, has also been described.[69-71]</TEXT>
				<SORT_TAG>1</SORT_TAG>
			</COMMENT_STRING>
			
		</COMMENT_DEFINITIONS>
		
	</DEFINITIONS>

<!-- RULES start here.  Each drug has two rules.
		- a rule that is always true but never shows a mutation hit;
				this guarantees that results will be shown for the drug.
		- a list of mutations that will trigger the rule;
				these are the ones in the relevant line of one of the IASUSA charts.
-->
<!-- PIs -->

	<!-- chart shows ATV with or without ritonavir; made into 2 drugs here -->
	<DRUG><NAME>ATV</NAME><FULLNAME>Atazanavir without ritonavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				50L OR 84V OR 88S OR 10IFVC OR 16E OR 20RMITV OR 24I OR 32I OR 33IFV OR 34Q OR 36ILV OR 46IL OR 48V OR 53LY OR 54LVMTA OR 60E OR 62V OR 64LMV OR 71VITL OR 73CSTA OR 82ATFI OR 85V OR 90M OR 93LM
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>
	
	<DRUG><NAME>ATV/r</NAME><FULLNAME>Atazanavir with ritonavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				50L OR 84V OR 88S OR 10IFVC OR 16E OR 20RMITV OR 24I OR 32I OR 33IFV OR 34Q OR 36ILV OR 46IL OR 48V OR 53LY OR 54LVMTA OR 60E OR 62V OR 64LMV OR 71VITL OR 73CSTA OR 82ATFI OR 85V OR 90M OR 93LM
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>

	<DRUG><NAME>DRV/r</NAME><FULLNAME>Darunavir/ritonavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>	  
				47V OR 50V OR 54ML OR 76V OR 84V OR 11I OR 32I OR 33F OR 74P OR 89V
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>

	<DRUG><NAME>FPV/r</NAME><FULLNAME>Fosamprenavir/ritonavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				50V OR 84V OR 10FIRV OR 32I OR 46IL OR 47V OR 54LVM OR 73S OR 76V OR 82AFST OR 90M
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>

	<DRUG><NAME>IDV/r</NAME><FULLNAME>Indinavir/ritonavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				46IL OR 82AFT OR 84V OR 10IRV OR 20MR OR 24I OR 32I OR 36I OR 54V OR 71VT OR 73SA OR 76V OR 77I OR 90M
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>

	<DRUG><NAME>LPV/r</NAME><FULLNAME>Lopinavir/ritonavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				32I OR 47VA OR 76V OR 82AFTS OR 10FIRV OR 20MR OR 24I OR 33F OR 46IL OR 50V OR 53L OR 54VLAMTS OR 63P OR 71VT OR 73S OR 84V OR  90M
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>

	<DRUG><NAME>NFV</NAME><FULLNAME>Nelfinavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				30N OR 90M OR 10FI OR 36I OR 46IL OR 71VT OR 77I OR 82AFTS OR 84V OR 88DS
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>
	
	<DRUG><NAME>SQV/r</NAME><FULLNAME>Saquinavir/ritonavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				48V OR 90M OR 10IRV OR 24I OR 54VL OR 62V OR 71VT OR 73S OR 77I OR 82AFTS OR 84V
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>

	<DRUG><NAME>TPV/r</NAME><FULLNAME>Tipranavir/ritonavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				47V OR 58E OR 74P OR 82LT OR 83D OR 84V OR 10V OR 33F OR 36ILV OR 43T OR 46L OR 54AMV OR 69KR OR 89IMV
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>

<!-- NRTI's, including pseudo-drugs representing multi-drug patterns -->

<!-- Multi-drug patterns -->

	<!-- RT69i defined as any insertion in RT67-71 -->
	<DRUG><NAME>RT69i_multi</NAME><FULLNAME>RT 69 insertion complex affecting all FDA-approved NRTIs</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				41L OR 62V OR 67i OR 68i OR 69i OR 70i OR 71i OR 70R OR 210W OR 215YF OR 219QE
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>
	
	<DRUG><NAME>RT151_multi</NAME><FULLNAME>RT 151 complex affecting all FDA-approved NRTIs except TDF</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				62V OR 75I OR 77L OR 116Y OR 151M
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>

	<DRUG><NAME>TAM_multi</NAME><FULLNAME>TAMs affecting all FDA-approved NRTIs</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				41L OR 67N OR 70R OR 210W OR 215YF OR 219QE
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>

<!-- particular NRTIs -->

	<DRUG><NAME>ABV</NAME><FULLNAME>Abacavir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				65R OR 74V OR 115F OR 184V
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>
	
	<DRUG><NAME>DDI</NAME><FULLNAME>Didanosine</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				65R OR 74V
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>
	
	<DRUG><NAME>FTC</NAME><FULLNAME>Emtricitabine</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				65R OR 184VI
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>
	
	<DRUG><NAME>3TC</NAME><FULLNAME>Lamivudine</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				65R OR 184VI
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>

	<DRUG><NAME>D4T</NAME><FULLNAME>Stavudine</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				41L OR 65R OR 67N OR 70R OR 210W OR 215YF OR 219QE
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>
	
	<DRUG><NAME>TDF</NAME><FULLNAME>Tenofovir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				65R OR 70E
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>

	<DRUG><NAME>ZDV</NAME><FULLNAME>Zidovudine</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				41L OR 67N OR 70R OR 210W OR 215YF OR 219QE
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>
	
<!-- NNRTIs - note that IAS does not inlcude DLV -->

	<DRUG><NAME>EFV</NAME><FULLNAME>Efavirenz</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				SELECT ATLEAST 1 FROM (100I,101P,103N,106M,108I,181CI,188L,190SA,225H)
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>
	</DRUG>

	<DRUG><NAME>ETR</NAME><FULLNAME>Etravirine</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				90I OR 98G OR 100I OR 101EHP OR 106I OR 138AGK OR 179DFT OR 181CIV OR 190SA OR 230L
			 </CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
   </DRUG>

	<DRUG><NAME>NVP</NAME><FULLNAME>Nevirapine</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
		  		100I OR 101P OR 103N OR 106AM OR 108I OR 181CI OR 188CLH OR 190A
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>

<!-- IHs - only one in IAS chart -->

	<DRUG><NAME>RAL</NAME><FULLNAME>Raltegravir</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		<RULE>
			<CONDITION>
				92Q OR 143RHC OR 148HKR OR 155H 
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>
	
<!-- EIs - only one in IAS chart -->

	<DRUG><NAME>ENF</NAME><FULLNAME>Enfuvirtide</FULLNAME>
		<RULE><CONDITION>EXCLUDE 999C</CONDITION><ACTIONS><LEVEL>1</LEVEL></ACTIONS></RULE>
		 <RULE>
			 <CONDITION>
				36DS OR 37V OR 38AME OR 39R OR 40H OR 42T OR 43D
			</CONDITION>
			<ACTIONS><LEVEL>1</LEVEL></ACTIONS>
		</RULE>			  
	</DRUG>

	<!-- next are the rules that trigger the appearance of the footnote text shown in the DEFINITIONS section -->

	<MUTATION_COMMENTS>
		
		<GENE><NAME>RT</NAME>
		
			<RULE>
				<CONDITION>208Y OR 215Y</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_a" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>SELECT ATLEAST 2 FROM (67i,68i,69i,70i,71i,69S) OR 41L OR 210W OR 215YF</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_b" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>151M</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_c" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>41L OR 67N OR 70R OR 210W OR 215YF OR 219QE OR 184V</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_d" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>SELECT ATLEAST 1 FROM (44D,118I) AND SELECT ATLEAST 1 FROM (41L,67N,70R,210W,215YF,219QE)</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_e" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>184V</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_f" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>65R</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_g" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>SELECT ATLEAST 3 FROM (41L,67N,210W,215YF,219QE) AND SELECT ATLEAST 1 FROM (70R,184V)</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_h" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>65R</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_i" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>184V</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_j" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>215ACDEGHILNSV</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_k" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>65R OR SELECT ATLEAST 3 FROM (41L,67N,210W,215YF,219QE)</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_l" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>181CIV OR 101P OR 100I</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_n" /></ACTIONS>
			</RULE>
			
		</GENE>
		
		<GENE><NAME>PR</NAME>
		
			<RULE>
				<CONDITION>50L OR 84V OR 88S OR 46I OR 76V</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_r" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>47V OR 54M OR 74P OR 84V OR 82A OR 50V OR 11I</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_s" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>47AV OR 32I OR 76V</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_u" /></ACTIONS>
			</RULE>
			<RULE>
				
				<CONDITION>30N</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_v" /></ACTIONS>
			</RULE>
			
			<RULE>
				<CONDITION>24I OR 150LV OR 53YLF OR 154L OR 76V</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_w" /></ACTIONS>
			</RULE>
			
		</GENE>
		
		<GENE><NAME>IN</NAME>
		
			<RULE>
				<CONDITION>SELECT ATLEAST 1 FROM (148HKR, 155H,143RHC) AND SELECT ATLEAST 1 FROM(74M,138AK,140S,92Q,97A,143H,163KR,151I,232N)</CONDITION>
				<ACTIONS><COMMENT ref="UserNote_z" /></ACTIONS>
			</RULE>
			
		</GENE>

	</MUTATION_COMMENTS>
	
</ALGORITHM>
